All Stories

  1. How large must a dose‐optimization trial be?
  2. Patient-Centered, Physician-Investigator Friendly Pragmatic Phase I/II Trial Designs—The 4P Model
  3. Comment on Wages et al, Coherence principles in interval-based dose finding. Pharmaceutical Statistics 2019, doi:10.1002/pst.1974
  4. Ethical Review and Methodologic Innovation in Phase 1 Cancer Trials
  5. Clinicians must regain control over phase 1 cancer combination-therapy trials
  6. The conduct of most first-in-human oncology drug trials is conceptually incoherent, and unethical.
  7. One-size-fits-all dosing in oncology wastes money, innovation and lives
  8. Dose Titration Algorithm Tuning (DTAT) should supersede ‘the’ Maximum Tolerated Dose (MTD) in oncology dose-finding trials
  9. One-size-fits-all dosing of cancer treatment drugs: How much does it cost society?
  10. A new concept may help us at last abandon one-size-fits-all dosing of cancer treatment drugs
  11. Dose Titration Algorithm Tuning (DTAT) should supersede the Maximum Tolerated Dose (MTD) concept in oncology dose-finding trials
  12. Casting a realist's eye on the real world of medicine: Against Anjum's ontological relativism
  13. Challenging an analysis of poverty, opportunity and PTSD in inner-city youth
  14. No Credible Alternative To 'The Basic Flaw'
  15. Housing Mobility and Adolescent Mental Health
  16. Financial Incentives to Control Hypertension in Patients
  17. Origins of Diagnostic Error
  18. Racial Disparities In Hospital Selection
  19. Community-Acquired Pneumonia and Proton Pump Inhibitors